A detailed history of Putnam Investments LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Putnam Investments LLC holds 272,146 shares of HALO stock, worth $16.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
272,146
Previous 267,191 1.85%
Holding current value
$16.2 Million
Previous $10.2 Million 1.45%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$33.32 - $42.1 $165,100 - $208,605
4,955 Added 1.85%
272,146 $10.1 Million
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $991,128 - $1.2 Million
27,184 Added 11.33%
267,191 $10.2 Million
Q2 2023

Aug 14, 2023

SELL
$30.28 - $38.74 $1.38 Million - $1.77 Million
-45,656 Reduced 15.98%
240,007 $8.66 Million
Q1 2023

May 22, 2023

SELL
$32.86 - $55.7 $793,141 - $1.34 Million
-24,137 Reduced 7.79%
285,663 $10.9 Million
Q4 2022

Feb 14, 2023

SELL
$40.06 - $59.44 $25,197 - $37,387
-629 Reduced 0.2%
309,800 $17.6 Million
Q3 2022

Nov 14, 2022

SELL
$38.53 - $51.78 $110,465 - $148,453
-2,867 Reduced 0.92%
310,429 $12.3 Million
Q2 2022

Aug 15, 2022

BUY
$37.35 - $48.3 $82,431 - $106,598
2,207 Added 0.71%
313,296 $13.8 Million
Q1 2022

May 16, 2022

SELL
$31.97 - $41.06 $283,893 - $364,612
-8,880 Reduced 2.78%
311,089 $12.4 Million
Q4 2021

Feb 14, 2022

BUY
$31.82 - $40.75 $331,373 - $424,370
10,414 Added 3.36%
319,969 $12.9 Million
Q3 2021

Nov 15, 2021

BUY
$38.47 - $46.42 $920,048 - $1.11 Million
23,916 Added 8.37%
309,555 $12.6 Million
Q1 2021

May 17, 2021

BUY
$39.51 - $51.45 $5.06 Million - $6.59 Million
128,016 Added 81.22%
285,639 $11.9 Million
Q4 2020

Feb 16, 2021

BUY
$25.81 - $43.62 $4.07 Million - $6.88 Million
157,623 New
157,623 $6.73 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.29B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Putnam Investments LLC Portfolio

Follow Putnam Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Putnam Investments LLC with notifications on news.